Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Economic analysis of pharmacist-administered influenza vaccines in Ontario, Canada.

O'Reilly DJ, Blackhouse G, Burns S, Bowen JM, Burke N, Mehltretter J, Waite NM, Houle SK.

Clinicoecon Outcomes Res. 2018 Oct 24;10:655-663. doi: 10.2147/CEOR.S167500. eCollection 2018.

2.

Is Screening for Atrial Fibrillation in Canadian Family Practices Cost-Effective in Patients 65 Years and Older?

Tarride JE, Quinn FR, Blackhouse G, Sandhu RK, Burke N, Gladstone DJ, Ivers NM, Dolovich L, Thornton A, Nakamya J, Ramasundarahettige C, Frydrych PA, Henein S, Ng K, Congdon V, Birtwhistle RV, Ward R, Healey JS.

Can J Cardiol. 2018 Nov;34(11):1522-1525. doi: 10.1016/j.cjca.2018.05.016. Epub 2018 Jun 21.

3.

Low-intensity pulsed ultrasound for treatment of tibial fractures: an economic evaluation of the TRUST study.

Tarride JE, Hopkins RB, Blackhouse G, Burke N, Bhandari M, Johal H, Guyatt GH, Busse JW.

Bone Joint J. 2017 Nov;99-B(11):1526-1532. doi: 10.1302/0301-620X.99B11.BJJ-2017-0737.

PMID:
29092994
4.

The premarket assessment of the cost-effectiveness of a predictive technology "Straticyte™" for the early detection of oral cancer: a decision analytic model.

Khoudigian-Sinani S, Blackhouse G, Levine M, Thabane L, O'Reilly D.

Health Econ Rev. 2017 Oct 2;7(1):35. doi: 10.1186/s13561-017-0170-6.

5.

Preliminary Results of the Adoption and Application of the Integrated Comprehensive Care Bundle Care Program When Treating Patients with Chronic Obstructive Pulmonary Disease.

Guertin JR, Bowen JM, Gosse C, Blackhouse G, O'Reilly DJ, Baltaga E, Cox G, Johnson D, Le Blanc B, Loncke J, Pugsley S, Sivakumaran R, Wheatley L, Smith K, Tarride JE.

Can Respir J. 2017;2017:7049483. doi: 10.1155/2017/7049483. Epub 2017 Aug 7.

6.

Screening for atrial fibrillation in Canadian pharmacies: an economic evaluation.

Tarride JE, Dolovich L, Blackhouse G, Guertin JR, Burke N, Manja V, Grinvalds A, Lim T, Healey JS, Sandhu RK.

CMAJ Open. 2017 Aug 22;5(3):E653-E661. doi: 10.9778/cmajo.20170042.

7.

Estimates of health utility scores in chronic kidney disease.

Sekercioglu N, Curtis B, Murphy S, Blackhouse G, Barrett B.

Int Urol Nephrol. 2017 Nov;49(11):2043-2049. doi: 10.1007/s11255-017-1664-1. Epub 2017 Jul 21.

PMID:
28733768
8.

The Integrated Comprehensive Care Program: A Novel Home Care Initiative After Major Thoracic Surgery.

Shargall Y, Hanna WC, Schneider L, Schieman C, Finley CJ, Tran A, Demay S, Gosse C, Bowen JM, Blackhouse G, Smith K.

Semin Thorac Cardiovasc Surg. 2016 Summer;28(2):574-582. doi: 10.1053/j.semtcvs.2015.12.003. Epub 2015 Dec 11.

PMID:
28043480
9.

DNA Mismatch Repair Deficiency Tumour Testing for Patients With Colorectal Cancer: A Health Technology Assessment [Internet].

Assasi N, Blackhouse G, Campbell K, Gaebel K, Hopkins R, Jegathisawaran J, Sinclair A, Seal K, Kamel C, Levine M, Blackhouse G, Tsoi B, Campbell K, Jegathisawaran J, Weeks L, Garland S, Moulton K, Kaunelis D.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug.

11.

Mismatch Repair Deficiency Testing for Patients with Colorectal Cancer: A Clinical and Cost-Effectiveness Evaluation [Internet].

Assasi N, Blackhouse G, Campbell K, Weeks L, Levine M.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Sep.

12.

Colon Capsule Endoscopy for the Detection of Colorectal Polyps: An Economic Analysis.

Palimaka S, Blackhouse G, Goeree R.

Ont Health Technol Assess Ser. 2015 Jul 1;15(15):1-43. eCollection 2015.

13.

Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: An Economic Analysis.

Babashov V, Palimaka S, Blackhouse G, O'Reilly D.

Ont Health Technol Assess Ser. 2015 Mar 1;15(5):1-61. eCollection 2015.

14.

Capsule Endoscopy in the Assessment of Obscure Gastrointestinal Bleeding: An Economic Analysis.

Palimaka S, Blackhouse G, Goeree R.

Ont Health Technol Assess Ser. 2015 Feb 1;15(2):1-32. eCollection 2015. Review.

15.

Systematic narrative review of decision frameworks to select the appropriate modelling approaches for health economic evaluations.

Tsoi B, O'Reilly D, Jegathisawaran J, Tarride JE, Blackhouse G, Goeree R.

BMC Res Notes. 2015 Jun 17;8:244. doi: 10.1186/s13104-015-1202-0. Review.

16.

Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management.

Tsoi B, Blackhouse G, Ferrazzi S, Reade CJ, Chen I, Goeree R.

Clinicoecon Outcomes Res. 2015 Apr 17;7:213-25. doi: 10.2147/CEOR.S78115. eCollection 2015.

17.

Do different decision-analytic modeling approaches produce different results? A systematic review of cross-validation studies.

Tsoi B, Goeree R, Jegathisawaran J, Tarride JE, Blackhouse G, O'Reilly D.

Expert Rev Pharmacoecon Outcomes Res. 2015 Jun;15(3):451-63. doi: 10.1586/14737167.2015.1021336. Epub 2015 Mar 2. Review.

PMID:
25728942
18.

Economic evaluation of an influenza immunization strategy of healthy children.

Gregg M, Blackhouse G, Loeb M, Goeree R.

Int J Technol Assess Health Care. 2014 Oct;30(4):394-9. doi: 10.1017/S0266462314000397. Epub 2014 Nov 21.

PMID:
25412647
19.

Point-of-Care Hemoglobin A1c Testing: A Budget Impact Analysis.

Chadee A, Blackhouse G, Goeree R.

Ont Health Technol Assess Ser. 2014 Jul 1;14(9):1-23. eCollection 2014.

20.

Cost-effectiveness of the carbon-13 urea breath test for the detection of Helicobacter pylori: an economic analysis.

Masucci L, Blackhouse G, Goeree R.

Ont Health Technol Assess Ser. 2013 Oct 1;13(20):1-28. eCollection 2013. Review.

21.

Cost-effectiveness of 64-slice CT angiography compared to conventional coronary angiography based on a coverage with evidence development study in Ontario.

Goeree R, Blackhouse G, Bowen JM, O'Reilly D, Sutherland S, Hopkins R, Chow B, Freeman M, Provost Y, Dennie C, Cohen E, Marcuzzi D, Iwanochko R, Moody A, Paul N, Parker JD.

Expert Rev Pharmacoecon Outcomes Res. 2013 Oct;13(5):675-90. doi: 10.1586/14737167.2013.838079.

PMID:
24138652
22.

Cost-effectiveness of catheter ablation for rhythm control of atrial fibrillation.

Blackhouse G, Assasi N, Xie F, Gaebel K, Campbell K, Healey JS, O'Reilly D, Goeree R.

Int J Vasc Med. 2013;2013:262809. doi: 10.1155/2013/262809. Epub 2013 Sep 8.

23.

Transcatheter aortic valve implantation (TAVI) for treatment of aortic valve stenosis: an evidence update.

Sehatzadeh S, Doble B, Xie F, Blackhouse G, Campbell K, Kaulback K, Chandra K, Goeree R.

Ont Health Technol Assess Ser. 2013 May 1;13(1):1-40. Print 2013. Review.

24.

Epilepsy care in ontario: an economic analysis of increasing access to epilepsy surgery.

Bowen JM, Snead OC, Chandra K, Blackhouse G, Goeree R.

Ont Health Technol Assess Ser. 2012;12(18):1-41. Epub 2012 Jul 1.

25.

Transcatheter aortic valve implantation (TAVI) for treatment of aortic valve stenosis: an evidence-based Analysis (part B).

Sehatzadeh S, Doble B, Xie F, Blackhouse G, Campbell K, Kaulback K, Chandra K, Goeree R.

Ont Health Technol Assess Ser. 2012;12(14):1-62. Epub 2012 May 1. Review.

26.

Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model.

Chandra K, Blackhouse G, McCurdy BR, Bornstein M, Campbell K, Costa V, Franek J, Kaulback K, Levin L, Sehatzadeh S, Sikich N, Thabane M, Goeree R.

Ont Health Technol Assess Ser. 2012;12(12):1-61. Epub 2012 Mar 1. No abstract available.

27.

Comparative effectiveness of catheter ablation strategies for rhythm control in patients with atrial fibrillation: a meta-analysis.

Assasi N, Xie F, Blackhouse G, Gaebel K, Robertson D, Hopkins R, Healey JS, Goeree R.

J Interv Card Electrophysiol. 2012 Dec;35(3):259-75. doi: 10.1007/s10840-012-9723-0. Epub 2012 Oct 3.

PMID:
23054128
28.

The excess burden of rheumatoid arthritis in Ontario, Canada.

Tarride JE, Haq M, Nakhai-Pour HR, O'Reilly DJ, Xie F, Dolovich L, Blackhouse G, Goeree R.

Clin Exp Rheumatol. 2013 Jan-Feb;31(1):18-24. Epub 2012 Oct 3.

PMID:
23043846
29.

Ablation procedures for rhythm control in patients with atrial fibrillation: clinical and cost-effectiveness analyses.

Assasi N, Blackhouse G, Xie F, Gaebel K, Robertson D, Hopkins R, Healey J, Roy D, Goeree R.

CADTH Technol Overv. 2012;2(1):e2101. Epub 2012 Mar 1. No abstract available.

30.
31.

Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.

Blackhouse G, Xie F, Levine MA, Campbell K, Assasi N, Gaebel K, O'Reilly D, Tarride J, Goeree R.

J Popul Ther Clin Pharmacol. 2012;19(2):e166-78. Epub 2012 May 1.

PMID:
22580389
32.

Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.

Blackhouse G, Assasi N, Xie F, Marshall J, Irvine EJ, Gaebel K, Campbell K, Hopkins R, O'Reilly D, Tarride JE, Goeree R.

J Crohns Colitis. 2012 Feb;6(1):77-85. doi: 10.1016/j.crohns.2011.07.007. Epub 2011 Sep 9.

PMID:
22261531
33.

Cost-effectiveness of a shared computerized decision support system for diabetes linked to electronic medical records.

O'Reilly D, Holbrook A, Blackhouse G, Troyan S, Goeree R.

J Am Med Inform Assoc. 2012 May-Jun;19(3):341-5. doi: 10.1136/amiajnl-2011-000371. Epub 2011 Nov 3.

34.

Using health technology assessment to support evidence-based decision-making in Canada: an academic perspective.

Xie F, Bowen JM, Sutherland SC, Burke N, Blackhouse G, Tarride JE, O'Reilly D, Goeree R.

Expert Rev Pharmacoecon Outcomes Res. 2011 Oct;11(5):513-21. doi: 10.1586/erp.11.60.

PMID:
21958096
35.

Should endovascular repair be reimbursed for low risk abdominal aortic aneurysm patients? Evidence from ontario, Canada.

Tarride JE, Blackhouse G, De Rose G, Bowen JM, Nakhai-Pour HR, O'Reilly D, Xie F, Novick T, Hopkins R, Goeree R.

Int J Vasc Med. 2011;2011:308685. doi: 10.1155/2011/308685. Epub 2011 Jun 24.

36.

Economic evaluation of reamed versus unreamed intramedullary nailing in patients with closed and open tibial fractures: results from the study to prospectively evaluate reamed intramedullary nails in patients with tibial fractures (SPRINT).

SPRINT Investigators, Briel M, Sprague S, Heels-Ansdell D, Guyatt G, Bhandari M, Blackhouse G, Sanders D, Schemitsch E, Swiontkowski M, Tornetta P 3rd, Walter SD, Goeree R.

Value Health. 2011 Jun;14(4):450-7. doi: 10.1016/j.jval.2010.10.034. Epub 2011 May 25. Erratum in: Value Health. 2011 Sep-Oct;14(6):963. multiple investigator names added.

37.

Triple therapy for the management of COPD: a review.

Gaebel K, McIvor RA, Xie F, Blackhouse G, Robertson D, Assasi N, Hernandez P, Goeree R.

COPD. 2011 Jun;8(3):206-43. doi: 10.3109/15412555.2011.560131. Epub 2011 Apr 22. Review.

PMID:
21513437
38.

Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada.

O'Reilly DJ, Xie F, Pullenayegum E, Gerstein HC, Greb J, Blackhouse GK, Tarride JE, Bowen J, Goeree RA.

Qual Life Res. 2011 Aug;20(6):939-43. doi: 10.1007/s11136-010-9828-9. Epub 2011 Jan 8.

PMID:
21221816
39.

General population versus disease-specific event rate and cost estimates: potential bias for economic appraisals.

Goeree R, O'Reilly D, Hopkins R, Blackhouse G, Tarride JE, Xie F, Lim M.

Expert Rev Pharmacoecon Outcomes Res. 2010 Aug;10(4):379-84. doi: 10.1586/erp.10.41. Review.

PMID:
20715915
40.

Conditionally funded field evaluations: PATHs coverage with evidence development program for Ontario.

Goeree R, Chandra K, Tarride JE, O'Reilly D, Xie F, Bowen J, Blackhouse G, Hopkins R.

Value Health. 2010 Jun;13 Suppl 1:S8-11. doi: 10.1111/j.1524-4733.2010.00747.x. No abstract available.

41.

Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation.

Hodge W, Brown A, Kymes S, Cruess A, Blackhouse G, Hopkins R, McGahan L, Sharma S, Pan I, Blair J, Vollman D, Morrison A.

Can J Ophthalmol. 2010 Jun;45(3):223-30. doi: 10.3129/i10-047. Review.

PMID:
20628420
42.

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada.

Blackhouse G, Gaebel K, Xie F, Campbell K, Assasi N, Tarride JE, O'Reilly D, Chalk C, Levine M, Goeree R.

Cost Eff Resour Alloc. 2010 Jun 17;8:14. doi: 10.1186/1478-7547-8-14.

43.

Patient outcomes after anti TNF-alpha drugs for Crohn's disease.

Assasi N, Blackhouse G, Xie F, Marshall JK, Irvine EJ, Gaebel K, Robertson D, Campbell K, Hopkins R, Goeree R.

Expert Rev Pharmacoecon Outcomes Res. 2010 Apr;10(2):163-75. doi: 10.1586/erp.10.13. Review.

PMID:
20384563
44.

A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment.

Tarride JE, Hopkins R, Blackhouse G, Bowen JM, Bischof M, Von Keyserlingk C, O'Reilly D, Xie F, Goeree R.

Pharmacoeconomics. 2010;28(4):255-77. doi: 10.2165/11531590-000000000-00000. Review.

PMID:
20222752
45.

Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.

Gaebel K, Blackhouse G, Campbell K, Robertson D, Xie F, Assasi N, Chalk C, Levine M, Goeree R.

Open Med. 2010;4(3):e154-66. Epub 2010 Aug 24.

46.

Paclitaxel versus sirolimus stents in diabetic and nondiabetic patients.

Chiu M, Ko DT, Austin PC, Cohen EA, Velianou JL, Goeree R, Blackhouse G, Tu JV.

Circ Cardiovasc Qual Outcomes. 2009 Mar;2(2):96-107. doi: 10.1161/CIRCOUTCOMES.108.826057. Epub 2009 Mar 5.

PMID:
20031821
47.

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis.

Xie F, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R.

Cost Eff Resour Alloc. 2009 Dec 11;7:20. doi: 10.1186/1478-7547-7-20.

48.

Impact of the 1997 Canadian guidelines on the conduct of Canadian-based economic evaluations in the published literature.

Lim ME, Bowen JM, O'Reilly D, McCarron CE, Blackhouse G, Hopkins R, Goeree R, Tarride JE.

Value Health. 2010 Mar-Apr;13(2):328-34. doi: 10.1111/j.1524-4733.2009.00613.x. Epub 2009 Sep 25. Review.

49.

Cost analysis of multiplex PCR testing for diagnosing respiratory virus infections.

Mahony JB, Blackhouse G, Babwah J, Smieja M, Buracond S, Chong S, Ciccotelli W, O'Shea T, Alnakhli D, Griffiths-Turner M, Goeree R.

J Clin Microbiol. 2009 Sep;47(9):2812-7. doi: 10.1128/JCM.00556-09. Epub 2009 Jul 1.

50.

Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.

Xie F, Blackhouse G, Assasi N, Campbell K, Levin M, Bowen J, Tarride JE, Pi D, Goeree R.

Clin Ther. 2009 May;31(5):1082-91; discussion 1066-8. doi: 10.1016/j.clinthera.2009.05.006.

PMID:
19539109

Supplemental Content

Loading ...
Support Center